In summary, our analysis showed that the ORR of BRAFi and MEKi in patients with BRAF-mutant advanced melanoma and germline CDKN2A PVs was not inferior to that observed in clinical trials and real-world studies, which we believe to be a relevant information for clinicians who manage CDKN2A PV carriers with BRAF-mutant melanoma. This evidence concerns the gene CDKN2A and melanoma.